InvitroCue Ltd (ASX:IVQ) has signed a strategic agreement with QIAGEN Suzhou Translational Medicine Co Ltd to jointly discover biomarkers for the Chinese biopharmaceutical market.
Biomarkers are measurable indicators of the severity or presence of a disease state.
InvitroCue will provide its proprietary 3D cellulosic scaffolding technology and cell-based assay to build in vitro screening models for QIAGEN Suzhou.
The companies will also collaborate on translational medicine research, which is a growing discipline in biomedical research which aims to expedite the discovery of new diagnostic tools and treatments.
The strategic partnership will be immediately revenue generating and be in effect for three years up to August 2019.
The first contract under the agreement is for an in vitro cell-based screening model.
Last month, InvitroCue established a collaboration with Switzerland’s InSphero AG to develop a novel assay to detect pancreatic toxicity by leveraging its cell-based technology.
The company has also introduced a suite of disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis and malaria.
Earlier in the year, InvitroCue entered the oncology testing market for drugs to provide data points in selected solid tumours.
The company had a cash balance of $1.76 million as at 30 June 2016.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.